Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow NovaBay Pharmaceuticals, Inc.

Get SEC filing alerts via email and in your feed for NovaBay Pharmaceuticals, Inc.

NBY

NovaBay Pharmaceuticals, Inc.

About NovaBay Pharmaceuticals, Inc.

NovaBay Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing proprietary antimicrobial products, primarily hypochlorous acid-based solutions for eye care, wound care, and dermatology. Its core offerings included Avenova eye spray and wound care products. The company operates in healthcare markets targeting consumers and medical professionals, emphasizing non-toxic, scientifically proven solutions. Currently, it is winding down operations, pursuing liquidation, or exploring strategic alternatives.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from NovaBay Pharmaceuticals, Inc.

1
1
NovaBay Pharmaceuticals, Inc. Stablecoin Development Corporation Reports $552.4M Net Income and $2.5M Staking Revenue for Q1 2026

Via official filing (AI summary) | 19 days ago | 0 comments

2
1
NovaBay Pharmaceuticals, Inc. NovaBay Pharmaceuticals Reports $33.2M Net Loss and Strategic Shift to Digital Assets

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
NovaBay Pharmaceuticals, Inc. NovaBay Pharmaceuticals Reports Q3 2025 Financial Results with Revenue Increase and Restructuring Updates

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
NovaBay Pharmaceuticals, Inc. NovaBay Pharmaceuticals Reports Increased Net Loss and Significant Cash Reserves Following Strategic Divestitures

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
NovaBay Pharmaceuticals, Inc. NovaBay Pharmaceuticals Reports $7.67 Million Net Income, Evaluates Potential Dissolution

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
NovaBay Pharmaceuticals, Inc. NovaBay Pharmaceuticals Reports Decrease in Sales and Plans Voluntary Dissolution

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
NovaBay Pharmaceuticals, Inc. NovaBay Pharmaceuticals Reports Financial Challenges, Pursues Asset Sale and Potential Dissolution

Via official filing (AI summary) | over 1 year ago | 0 comments